Literature DB >> 7678615

Identification of multiple T cell epitopes on Bet v I, the major birch pollen allergen, using specific T cell clones and overlapping peptides.

C Ebner1, Z Szépfalusi, F Ferreira, A Jilek, R Valenta, P Parronchi, E Maggi, S Romagnani, O Scheiner, D Kraft.   

Abstract

Eleven T cell clones (TCC) with specificity for Bet v I were established from the peripheral blood of six birch pollen allergic donors. Bet v I is the major allergen of birch (Betula verrucosa) pollen and shows high homology to the major allergens of pollens of other trees within the order fagales (hazel, alder, hornbeam, oak, etc.), which represent important inhalant allergens in the northern hemisphere. The TCC were shown to react with purified natural, as well as with purified recombinant Bet v I. All clones showed the helper cell phenotype (CD3+CD4+) and expressed the TCR-alpha/beta. The cytokine production pattern in response to stimulation with allergen resulted in enhanced production of IL-4 in 9 of 11 clones. The clones were used for T cell epitope mapping on the Bet v I molecule. For this purpose, peptides with a length of 12 amino acids each and overlapping for 10 residues were synthesized following the amino acid sequence of Bet v I. These 75 peptides were used to stimulate Bet v I-specific T cell clones. Our experiments revealed 7 distinct T cell epitopes on the Bet v I molecule. The epitopes were scattered over the whole molecule, 2 sequences were in agreement with an algorithm previously described for the prediction of T cell epitopes. In 3 cases, we could identify distinct TCC specificities within single individuals. Furthermore, for each donor, none of the peptides representing epitopes for TCC inhibited the binding of IgE antibodies to Bet v I. These results suggest that T cells and IgE antibodies from the same individual recognize different structures on the Bet v I allergen.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7678615

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  19 in total

Review 1.  Molecular characterization of allergens.

Authors:  S S Mohapatra; R F Lockey
Journal:  Clin Rev Allergy Immunol       Date:  2001-10       Impact factor: 8.667

2.  Multiple B- and T-cell epitopes on a major allergen of Kentucky Bluegrass pollen.

Authors:  L Zhang; M Yang; P Chong; S S Mohapatra
Journal:  Immunology       Date:  1996-02       Impact factor: 7.397

3.  Use of multiple peptides containing T cell epitopes is a feasible approach for peptide-based immunotherapy in Can f 1 allergy.

Authors:  Anu K Immonen; Antti H Taivainen; Ale T O Närvänen; Tuure T Kinnunen; Soili A Saarelainen; Marja A Rytkönen-Nissinen; Tuomas I Virtanen
Journal:  Immunology       Date:  2007-01       Impact factor: 7.397

Review 4.  How diverse--CD4 effector T cells and their functions.

Authors:  Yisong Y Wan; Richard A Flavell
Journal:  J Mol Cell Biol       Date:  2009-05-28       Impact factor: 6.216

5.  Conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T cell epitope-containing fragments: candidates for a novel form of specific immunotherapy.

Authors:  S Vrtala; K Hirtenlehner; L Vangelista; A Pastore; H G Eichler; W R Sperr; P Valent; C Ebner; D Kraft; R Valenta
Journal:  J Clin Invest       Date:  1997-04-01       Impact factor: 14.808

Review 6.  Regulatory T cells: immune suppression and beyond.

Authors:  Yisong Y Wan
Journal:  Cell Mol Immunol       Date:  2010-04-12       Impact factor: 11.530

Review 7.  Proteomics for Allergy: from Proteins to the Patients.

Authors:  Emmanuel Nony; Maxime Le Mignon; Sébastien Brier; Armelle Martelet; Philippe Moingeon
Journal:  Curr Allergy Asthma Rep       Date:  2016-09       Impact factor: 4.806

Review 8.  Recombinant allergens: the present and the future.

Authors:  Marek Jutel; Katarzyna Solarewicz-Madejek; Sylwia Smolinska
Journal:  Hum Vaccin Immunother       Date:  2012-10-01       Impact factor: 3.452

9.  A nonallergenic birch pollen allergy vaccine consisting of hepatitis PreS-fused Bet v 1 peptides focuses blocking IgG toward IgE epitopes and shifts immune responses to a tolerogenic and Th1 phenotype.

Authors:  Katharina Marth; Isabella Breyer; Margarete Focke-Tejkl; Katharina Blatt; Mohamed H Shamji; Janice Layhadi; Anna Gieras; Ines Swoboda; Domen Zafred; Walter Keller; Peter Valent; Stephen R Durham; Rudolf Valenta
Journal:  J Immunol       Date:  2013-02-25       Impact factor: 5.422

10.  Different growth factor requirements for human Th2 cells may reflect in vivo induced anergy.

Authors:  F C Van Reijsen; O L Wijburg; M Gebhardt; A G Van Ieperen-Van Dijk; S Betz; E M Poellabauer; T Thepen; C A Bruijnzeel-Koomen; G C Mudde
Journal:  Clin Exp Immunol       Date:  1994-10       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.